After the initial chemotherapy, patients will be divided into two groups. One group will receive a medication called niraparib alone, while the other group will receive niraparib combined with bevacizumab. Niraparib is taken as a capsule by mouth, while bevacizumab is given through an intravenous infusion. The purpose of this study is to determine if adding bevacizumab to niraparib treatment leads to better results than using niraparib alone.

The study will monitor how long patients remain without their cancer getting worse. Patients will receive regular medical examinations and tests throughout the study period. The treatment may continue for up to 36 months, depending on how well patients respond to the therapy and whether they experience any side effects.

The purpose of the study is to determine the best dose of IMGN151 that can be safely given to patients and to see how well it works in treating these cancers. The study will be conducted in two main phases. In the first phase, different doses of IMGN151 will be tested to find the safest and most effective dose. In the second phase, the chosen dose will be given to more patients to further assess its effectiveness. Throughout the study, participants will receive IMGN151 through an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

Participants in the study will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study aims to provide valuable information about the potential benefits and risks of IMGN151 for women with these specific types of recurrent cancers. This research is important for developing new treatment options that could improve outcomes for patients facing these challenging conditions.

The purpose of this study is to evaluate how well Pembrolizumab works in patients with these specific types of cancer. The study will look at how long patients live after receiving the treatment, which is referred to as overall survival. Additionally, the study will monitor other aspects such as the side effects of the treatment, how the cancer responds to the treatment, how long patients live without the cancer getting worse, and the overall quality of life of the patients during the study.

Participants in the study will receive Pembrolizumab as a single treatment over a period of up to 24 months. The study is designed to gather information on the effectiveness and safety of Pembrolizumab in treating these cancers. By participating in this study, researchers hope to gain valuable insights that could help improve treatment options for patients with these challenging types of cancer in the future.

Participants in the study will be divided into different groups to receive either the medications or a placebo. The study will compare the effects of taking Rucaparib alone, Rucaparib combined with Nivolumab, or a placebo. The trial will monitor the progression of the disease and overall survival rates among participants. The study aims to determine if these treatments can help maintain the positive effects of the initial chemotherapy and delay the progression of the cancer.

The trial will be conducted over several years, with participants receiving treatment and being monitored for any changes in their condition. The study will use specific criteria to evaluate the effectiveness of the treatments, such as the time it takes for the disease to progress or for any adverse effects to occur. The results will help determine the potential benefits of using Rucaparib and Nivolumab as part of a long-term treatment plan for patients with advanced ovarian cancer.

The purpose of this study is to compare the effectiveness of different combinations of these medications in patients with advanced ovarian, primary peritoneal, and Fallopian tube cancer. The study will explore how well these treatments work based on the Homologous Recombination Deficient (HRD) status of the patients, which is a specific characteristic of the cancer cells that can affect how they respond to treatment. The trial will begin with a phase to determine the safest dose of the combination of Rucaparib and Bevacizumab, followed by a phase to compare the progression-free survival of patients receiving different treatment combinations.

Participants in the study will receive one of the following treatment combinations: Carboplatin, Paclitaxel, and Bevacizumab; Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib; or Carboplatin, Paclitaxel, and Rucaparib. The study will monitor the patients over time to assess how long they live without the cancer getting worse. The trial aims to provide valuable information on the best treatment options for patients with these types of cancer, based on their HRD status.

Participants in the study will undergo one of two types of surgeries: Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS). These surgeries are performed to remove as much of the cancer as possible. After the surgery, some patients will receive the HIPEC treatment, while others will receive standard care without HIPEC. The study will compare the outcomes of these two groups to see if the HIPEC treatment is more effective. The study will also monitor the overall survival of patients and any side effects they may experience during the treatment.

The trial will follow participants over a period of time to assess their disease-free survival (DFS), which means the length of time they live without the cancer returning. Researchers will also evaluate the overall quality of life of the participants using questionnaires. The study aims to provide valuable information on whether adding HIPEC to standard surgical treatment can improve outcomes for patients with ovarian cancer.

Participants in the study will receive their treatments through an infusion, which means the medication is given directly into a vein. The study will follow patients over a period of time to monitor their health and the progression of their cancer. The main goal is to determine if the addition of Oregovomab can improve the time patients live without their cancer progressing, which is known as progression-free survival. The study will also look at overall survival, which is the length of time patients live after starting the treatment, and any side effects that may occur.

This trial is designed to provide important information about the potential benefits of Oregovomab when used alongside standard chemotherapy for patients with advanced ovarian cancer. By comparing the two groups, researchers hope to find out if this new treatment can offer better outcomes for patients facing these challenging conditions.

Participants in the study will receive ZN-c3 in the form of film-coated tablets taken orally. The study will be conducted in two parts. In the first part, the focus will be on determining the safety and how well patients can tolerate ZN-c3. The second part will investigate the medication’s ability to reduce or eliminate the cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of ZN-c3.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the cancer’s response to the treatment. The goal is to gather information that could lead to better treatment options for patients with this type of cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to see how well MORAb-202 works compared to the other chemotherapy treatments. Participants in the study will receive either the new treatment or one of the standard chemotherapy options, which may include drugs like Caelyx (containing doxorubicin hydrochloride), paclitaxel, or topotecan. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience. The main goal is to determine the effectiveness of MORAb-202 in treating this type of cancer and to assess the safety of the treatment. Participants will be closely monitored by healthcare professionals throughout the study to ensure their well-being and to gather important information about the treatment’s impact on their cancer.

The purpose of the study is to evaluate how well Raludotatug Deruxtecan works compared to other treatments that doctors might choose, such as paclitaxel, doxorubicin hydrochloride, liposomal, gemcitabine hydrochloride, or topotecan. These are all medications that are commonly used to treat cancer. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will be randomly assigned to receive either Raludotatug Deruxtecan or one of the other treatments. The study will take place over a period of up to 24 months. During this time, participants will have regular visits to monitor their health and the effects of the treatment. The study aims to provide more information about the effectiveness and safety of Raludotatug Deruxtecan for treating these types of cancer.

In addition to bevacizumab, other medications used in this study include olaparib, carboplatin, and paclitaxel. Olaparib is taken orally in the form of a tablet, while carboplatin and paclitaxel are given as infusions. The study will involve several groups of patients who will receive different combinations of these medications, including a placebo group. The treatment period for each patient can last up to 76 weeks, depending on the specific medications they receive.

The main goal of the study is to see if the lower dose of bevacizumab is as effective as the standard dose in preventing the progression of the disease. Throughout the study, researchers will monitor the patients’ response to the treatment and any side effects they may experience. The study will also assess the overall quality of life of the participants using standardized questionnaires. This research is important for understanding how to best use bevacizumab and other medications in treating these types of cancer.